Adar1 Capital Management, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1940272) · Explore on the interactive board
Adar1 Capital Management, LLC disclosed 267 US equity positions worth $2.1bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ABVX at 11.3% of the reported book, followed by PTGX, ROIV. The top ten holdings are 41.9% of the book, and the portfolio behaves like about 35 equal-weight positions. Versus the prior filing it opened 44 new positions, added to 94, reduced 63 and exited 25. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Adar1 Capital Management, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 44 new, 94 added, 63 reduced, 25 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | Healthcare | 11.3% | $240.5m | 1,804,703 | 29% | added |
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 5.5% | $117.8m | 960,863 | -3% | reduced |
| 3 | ROIV ROIVANT SCIENCES LTD | Healthcare | 5.3% | $111.7m | 3,157,008 | -4% | reduced |
| 4 | SPY STATE STR SPDR S&P 500 ETF T | 4.5% | $96.4m | 129,087 | 70% | added | |
| 5 | IMVT IMMUNOVANT INC | Healthcare | 4.2% | $89.8m | 2,330,716 | -13% | reduced |
| 6 | ZLAB ZAI LAB LTD | Healthcare | 3.0% | $64.0m | 3,369,034 | 136% | added |
| 7 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.2% | $47.8m | 1,288,053 | 816% | added |
| 8 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 2.1% | $45.7m | 1,222,080 | 7% | added | |
| 9 | BOXX EA SERIES TRUST | 1.9% | $39.5m | 337,125 | 0% | held | |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 1.8% | $39.0m | 457,907 | -28% | reduced |
| 11 | SEPN SEPTERNA INC | Healthcare | 1.5% | $31.5m | 940,747 | -14% | reduced |
| 12 | AVR ANTERIS TECHNOLOGIES GLOBAL | 1.5% | $31.0m | 3,145,096 | -17% | reduced | |
| 13 | EDIT EDITAS MEDICINE INC | Healthcare | 1.4% | $28.8m | 8,889,000 | – | new |
| 14 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.2% | $26.5m | 1,029,080 | -45% | reduced |
| 15 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.2% | $25.2m | 283,982 | -16% | reduced |
| 16 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.2% | $25.0m | 2,456,677 | -10% | reduced |
| 17 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.2% | $24.9m | 74,253 | 4850% | added |
| 18 | INSM INSMED INC | Healthcare | 1.1% | $24.4m | 228,520 | 546% | added |
| 19 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.1% | $23.1m | 619,542 | 45% | added |
| 20 | VKTX VIKING THERAPEUTICS INC | Healthcare | 1.1% | $22.4m | 574,038 | 152% | added |
| 21 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.0% | $20.7m | 3,040,466 | 2% | added |
| 22 | MNPR MONOPAR THERAPEUTICS INC | 0.9% | $20.1m | 217,595 | -18% | reduced | |
| 23 | OVID OVID THERAPEUTICS INC | Healthcare | 0.9% | $20.0m | 7,417,479 | 63% | added |
| 24 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.9% | $19.7m | 387,718 | 18% | added |
| 25 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 0.9% | $19.6m | 1,344,510 | 2518% | added |
| 26 | NKTR NEKTAR THERAPEUTICS | Healthcare | 0.8% | $17.0m | 244,184 | 51% | added |
| 27 | INSP INSPIRE MED SYS INC | Healthcare | 0.8% | $16.7m | 374,617 | -8% | reduced |
| 28 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.8% | $16.4m | 87,509 | -35% | reduced |
| 29 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.7% | $15.9m | 185,619 | -13% | reduced |
| 30 | PRTA PROTHENA CORP PLC | Healthcare | 0.7% | $15.2m | 1,554,535 | -2% | reduced |
| 31 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.7% | $15.1m | 136,158 | -36% | reduced |
| 32 | IKT INHIBIKASE THERAPEUTICS INC | 0.7% | $15.0m | 7,387,205 | 12% | added | |
| 33 | UNIQURE NV | 0.7% | $15.0m | 324,672 | 326% | added | |
| 34 | RLYB RALLYBIO CORP | 0.7% | $14.8m | 926,352 | 4411% | added | |
| 35 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.7% | $13.8m | 22,208 | 83% | added |
| 36 | IVA INVENTIVA SA | 0.6% | $13.6m | 3,606,656 | 66% | added | |
| 37 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.6% | $13.4m | 404,014 | -23% | reduced |
| 38 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 0.6% | $13.2m | 166,286 | 4% | added |
| 39 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.6% | $13.2m | 176,689 | 87% | added |
| 40 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 0.6% | $13.1m | 730,649 | 179% | added |
| 41 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 0.6% | $12.6m | 3,365,118 | -1% | reduced |
| 42 | VOR VOR BIOPHARMA INC | Healthcare | 0.6% | $12.5m | 680,626 | – | new |
| 43 | BIL SPDR SERIES TRUST | 0.6% | $12.4m | 135,585 | 0% | held | |
| 44 | EQ EQUILLIUM INC | 0.6% | $12.0m | 3,758,569 | 1% | added | |
| 45 | ANL ADLAI NORTYE LTD | 0.6% | $11.7m | 1,017,805 | 763% | added | |
| 46 | CLYM CLIMB BIO INC | Healthcare | 0.5% | $10.7m | 822,649 | 38% | added |
| 47 | HELIX ACQUISITION CORP III | 0.5% | $10.6m | 1,000,000 | 0% | held | |
| 48 | ZURA ZURA BIO LTD | Healthcare | 0.5% | $10.4m | 1,759,295 | 179% | added |
| 49 | OKUR ONKURE THERAPEUTICS INC | 0.5% | $10.2m | 2,238,684 | -8% | reduced | |
| 50 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.5% | $10.1m | 339,276 | 577% | added |
What did Adar1 Capital Management, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 430 TERNS PHARMACEUTICALS INC | 26.8% | $48.2m |
| BEAM BEAM THERAPEUTICS INC | 19.2% | $34.5m |
| SRRK SCHOLAR ROCK HLDG CORP | 11.1% | $20.0m |
| VRTX VERTEX PHARMACEUTICALS INC | 3.7% | $6.7m |
| VRDN VIRIDIAN THERAPEUTICS INC | 3.3% | $6.0m |
| ASND ASCENDIS PHARMA A/S | 3.2% | $5.7m |
| LLY ELI LILLY & CO | 2.6% | $4.7m |
| DNTH DIANTHUS THERAPEUTICS INC | 2.6% | $4.6m |
| BLTE BELITE BIO INC | 2.4% | $4.3m |
| ACLXGBX ARCELLX INC | 2.0% | $3.7m |
| AVBP ARRIVENT BIOPHARMA INC | 1.8% | $3.3m |
| APLSUSD APELLIS PHARMACEUTICALS INC | 1.6% | $2.9m |
| MASI* MASIMO CORP | 1.5% | $2.7m |
| TFX TELEFLEX INCORPORATED | 1.4% | $2.5m |
| BIOA BIOAGE LABS INC | 1.3% | $2.4m |
| ALKS ALKERMES PLC | 0.9% | $1.6m |
| SLNOEUR SOLENO THERAPEUTICS INC | 0.9% | $1.6m |
| CNTA CENTESSA PHARMACEUTICALS PLC | 0.9% | $1.5m |
| AM6 AMICUS THERAPEUTIC | 0.8% | $1.5m |
| UNH UNITEDHEALTH GROUP INC | 0.8% | $1.5m |
| SXT SENSIENT TECHNOLOGIES CORP | 0.7% | $1.3m |
| SDGR SCHRODINGER INC | 0.6% | $1.2m |
| FDMT 4D MOLECULAR THERAPEUTICS IN | 0.6% | $1.1m |
| DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 0.6% | $1.1m |
| BMY BRISTOL-MYERS SQUIBB CO | 0.6% | $1.1m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 73.5% |
| Financial Services | 0.3% |
| Real Estate | 0.0% |
| Communication Services | 0.0% |
| Consumer Cyclical | 0.0% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Adar1 Capital Management, LLC's portfolio?
Across every quarter Adar1 Capital Management, LLC has filed, its median largest position is 10.3% of the book and its median top-ten weight is 41.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 69.0 completed holding spells, the median lasted 1.0 quarters; 265.0 positions are still open and their final length is unknown.